Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 9/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | FNTA | P49354 | 6/20 | 0.34 |
| ▸ | FNTB | P49356 | 6/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | SLC6A15 | Q9H2J7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6737705 | 0.85 | ALDH1A1 (0.37) | ALDH1A1MAPTF10FNTAFNTB | |
| SCHEMBL6730709 | 0.82 | LSS (0.49) | ALDH1A1 | |
| SCHEMBL6726423 | 0.75 | MAPT (0.37) | CYP11B2ALDH1A1MAPTF10FNTA | |
| SCHEMBL6729950 | 0.74 | AKR1C3 (0.44) | CYP11B1MAPTFNTAFNTB | |
| SCHEMBL6730820 | 0.72 | ALDH1A1 (0.38) | ALDH1A1MAPTF10 | |
| SCHEMBL6726196 | 0.72 | F10 (0.41) | CYP11B1ALDH1A1MAPTF10 | |
| SCHEMBL6735885 | 0.71 | F10 (0.41) | ALDH1A1MAPTF10MGLL | |
| SCHEMBL6732153 | 0.70 | ALDH1A1 (0.37) | ALDH1A1MAPTF10 | |
| SCHEMBL6728488 | 0.70 | ALDH1A1 (0.38) | ALDH1A1MAPTF10 | |
| SCHEMBL6725420 | 0.69 | ALDH1A1 (0.38) | ALDH1A1MAPTF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | CYP11B2 131/4885CYP11B1 169/4885ALDH1A1 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.